Can Norethindrone (a progestin) suppress endometriosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Norethindrone can be used to suppress endometriosis, as it is a progestin medication that works by thinning the endometrial lining and inhibiting the growth of endometrial tissue outside the uterus. According to the American College of Obstetricians and Gynecologists (ACOG) recommendations 1, progestins, such as norethindrone, are effective in reducing the size of endometriotic lesions and alleviating symptoms. The typical dosage of norethindrone acetate for endometriosis treatment is 5-15 mg daily, taken continuously, with patients usually starting at a lower dose and increasing gradually based on symptom control and side effect tolerance. Some key points to consider when using norethindrone for endometriosis treatment include:

  • Common side effects: irregular bleeding, weight gain, mood changes, and breast tenderness
  • Improvement in symptoms: may take 2-3 months
  • Treatment duration: often continued for extended periods, as symptoms typically return when medication is stopped
  • Cost-effectiveness: norethindrone is generally more affordable than other endometriosis treatments
  • Alternative therapy: can be used as first-line therapy or as an alternative when other treatments aren't suitable It's essential to note that while norethindrone can suppress endometriosis, it may not eradicate the lesions, and there is no evidence that it affects future fertility outcomes 1. However, norethindrone can be a valuable treatment option for managing endometriosis symptoms, especially for patients who cannot tolerate other treatments or prefer a more affordable alternative.

From the FDA Drug Label

CLINICAL PHARMACOLOGY 1. Mode of Action Norethindrone tablets progestin-only oral contraceptives prevent conception by suppressing ovulation in approximately half of users, thickening the cervical mucus to inhibit sperm penetration, lowering the mid-cycle LH and FSH peaks, slowing the movement of the ovum through the fallopian tubes, and altering the endometrium.

The FDA drug label does not answer the question.

From the Research

Norethindrone and Endometriosis

  • Norethindrone acetate (NA) has been shown to be effective in suppressing endometriosis symptoms, with a significant decrease in pain and bleeding scores in patients with surgically diagnosed endometriosis 2.
  • The use of NA alone as a single-agent hormonal therapy has been found to be well-tolerated and effective in managing pain and bleeding for all stages of endometriosis 2.
  • Combination therapy with oral GnRH antagonists, such as relugolix, and norethindrone acetate has also been shown to be effective in reducing endometriosis-related pelvic pain, with an improved side effect profile 3.

Mechanism of Action

  • Norethindrone acetate has both estrogenic and androgenic properties, which allows it to exert beneficial effects on bone mineral density and vasomotor symptoms, while also exhibiting strong endometrial antiproliferative effects 4.
  • The hormonal profile of norethindrone acetate makes it a suitable add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis, allowing for the alleviation of hypoestrogenic symptoms while preserving therapeutic efficacy 4.

Comparison with Other Treatments

  • Shifting from oral contraceptives to norethisterone acetate, or vice versa, due to drug intolerance has been found to improve tolerability in women with endometriosis, with better results observed when substituting norethisterone acetate with oral contraceptives 5.
  • Progestins, including norethisterone acetate, are considered first-line treatment for endometriosis-related pain, with reduced side effects compared to other hormonal therapies 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.